The latest biotech news

News and Trends 20 Jul 2015

Theravectys’ HIV Cure on the Road to Success

Theravectys just announced positive results of its HIV drug candidate in a phase I/II study. The therapeutic vaccine using lentivirus could be the first cure available for the 35 million people currently suffering from this worldwide epidemic. Paris-based Theravectys presented detailed results from its phase I/II study at the 2015 Towards an HIV Cure Symposium in Vancouver, Canada. The trial currently enrolled 38 HIV-positive patients […]

July 20, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 20 Jul 2015

European Biotechs Outperform, Here is the Proof

We underwent great Biotech stories in 2014. However, was 2014 really a good year for the Biotech industry? EY released Beyond borders 2015, its 29th Biotechnology Industry Report. We summed up the most important details for you concerning the European Biotech sector. So, let’s go over a few statistics. First impression, the Biotech industry is definitely […]

July 20, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 20 Jul 2015

DBV raised €255M on the NASDAQ

[Update 20/07/2015] After successfully closing its Underwritten Public Offering, DBV finally raised €255M ($281,5M) on the NASDAQ. Original article from 16/07/2015: DBV Technologies is going for its second fundraising on the NASDAQ, hoping for €223M. €68.6M were already secured last week from Baker Bros. Advisors LP. The money will allow the company to stay independent all […]

July 20, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 17 Jul 2015

TC BioPharm raises €1.7M to commence treatment in UK cancer patients

TC BioPharm raised €1.7M (£1.18) to treat UK-based patients with melanoma, lung and kidney cancer. Thanks to this funding, the Phase I/II clinical studies will start as of September in several parts of the country. TC BioPharm’s lead product, ImmuniCell, uses patients’ own cells grown in culture to target a wide variety of different cancers. […]

July 17, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 17 Jul 2015

GSK and Partners Bavarian Nordic and J&J Ebola vaccine candidates both reach Phase II

In outbreak situations such as the Ebola crisis, vaccines play an essential role that was largely needed during the 2014 health emergency, especially when the plague reached the First World. To ensure preparedness against Ebola, now and in the future, companies have been rushing to develop vaccines against this disease. GSK has come up with […]

July 17, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 17 Jul 2015

AC Immune receives Milestone Payment for Alzheimer Antibody

AC Immune received a first milestone payment from Roche’s subsidiary Genentech. The latter picked up a potential Alzheimer’s drug worth developing towards clinical trials. The collaboration began in 2012 with Genentech’s promising milestone payments amounting to more than €384M (CHF400M). Alzheimer’s disease will be one of the biggest burdens of tomorrow’s society showing a dramaticaly […]

July 17, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 16 Jul 2015

Imperial Innovations receives a €71M loan from the European Investment Bank

Imperial Innovations secured another loan facility from the European Investment Bank (EIB) to support the company’s investments in the UK biotech and life science sector. This €71.3M (£50 million) funding follows a previous €42.9M (£30 million) loan granted by the EIB in July 2013. The European Investment Bank, which last year provided €13.3Bn to enhance […]

July 16, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 16 Jul 2015

Sanofi’s Extreme Makeover gives prominence to Genzyme

There seems to be a tendency towards revolution amongst Sanofi’s CEOs. Olivier Brandicourt, Managing director of the French drugmaker since his €4.1M golden handshake with the company, has come up with a restructuration plan that will reduce Sanofi’s business units from seven to five. The French businessman expects this reorganization will help the company to […]

July 16, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 16 Jul 2015

A Brand New Feature on Labiotechmap for our 3000 lovely Users

Are you guys kidding us ??? There are now over 3000 users on Labiotechmap.com! You have no idea how happy that makes us and how thankful we are! You guys are truly AMAZING 😀 On this special occasion we would like to let you guys know we added a brand new feature to make Labiotechmap even […]

July 16, 2015 - 1 minutemin - By Alexandre Lowrey

News and Trends 16 Jul 2015

Immunocore Skyrocketed by Europe’s Largest Private Biotech Financing Ever

Immunocore Limited, just announced that it has secured a £205 million financing (€293 m) from private investors to push forward its T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune diseases. This substantial amount of cash not only embodies the largest private investment ever made in Europe by a biotech company, but also the second […]

July 16, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 15 Jul 2015

How Servier saved Cellectis, the French CAR-T Miracle

Cellectis, the €1bn CAR-T company, just announced it reached a significant milestone in its collaboration with Servier. Surprisingly, early 2014, Cellectis and its 300 employees were only three months away from bankruptcy, mainly because of the competing gene-editing technology CRISPR. How and why did Servier save them? Let’s find out. Cellectis was founded in 1999 in Paris and […]

July 15, 2015 - 5 minutesmins - By Philip Hemme

News and Trends 15 Jul 2015

Ferring bets on bacteriophages to treat inflammatory bowel disease

Bacteriophages have been instinctively killing bacteria for millions of years. These natural bacteria predators represent a potential alternative to antibiotics and Ferring Pharmaceuticals wants to use them against inflammatory bowel disease. The Swiss pharma joined forces with phages specialist Intralytix to manufacture these viruses for clinical purposes. Bacteriophages can be very selective when it comes […]

July 15, 2015 - 2 minutesmins - By Philip Hemme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Theravectys’ HIV Cure on the Road to Success

European Biotechs Outperform, Here is the Proof

DBV raised €255M on the NASDAQ

TC BioPharm raises €1.7M to commence treatment in UK cancer patients

GSK and Partners Bavarian Nordic and J&J Ebola vaccine candidates both reach Phase II

AC Immune receives Milestone Payment for Alzheimer Antibody

Imperial Innovations receives a €71M loan from the European Investment Bank

Sanofi’s Extreme Makeover gives prominence to Genzyme

A Brand New Feature on Labiotechmap for our 3000 lovely Users

Immunocore Skyrocketed by Europe’s Largest Private Biotech Financing Ever

How Servier saved Cellectis, the French CAR-T Miracle

Ferring bets on bacteriophages to treat inflammatory bowel disease

Subscribe to our newsletter to get the latest biotech news!